Novacyt shares collapse after failure to renew UK supply contract

0
425
18237500 - businessman hand pointing to investment as concept
imageStock Markets11 hours ago (Apr 09, 2021 13:37)

© Reuters

By Samuel Indyk

Investing.com – Shares in Novacyt have fallen over 30% on Friday after the company’s supply contract with the UK Department of Health and Social Care (DHSC) was not renewed.

Anglo-French company Novacyt (LON:NCYT) makes the exsig Covid-19 direct kits and other products and had a previous supply agreement with the DHSC. Back in January this year, the company said it was in active discussions with the DHSC regarding an extension of the contract but an extension has not been agreed, although the company provided PROmate in Q1 2021 in accordance with demand from the DHSC.

The company has said the two parties are now in dispute regarding the contract which may have a material impact on Q4 2020 revenues. Novacyt is taking legal advice and believes it has strong grounds to assert contractual rights.

The company reported Q1 revenue of EUR 83.0 million although noted that approximately 50% of that was driven by sales to the DHSC, predominantly PROmate.

Novacyt expects PROmate to continue to be rolled out in private settings, international markets and hospitals for the foreseeable future but Q1 PROmate sales may be sufficient to support the NHS current rollout plans for the rest of 2021.

“Whilst the Directors are confident new contract wins will continue as Novacyt expands international sales and into private sector testing, they believe revenue and profit for 2021 may be lower than current market expectations due to the absence of the DHSC contract extension,” the company said in a statement.

At 13:35BST, Novacyt shares were trading lower by 39% at 425p.

Novacyt shares collapse after failure to renew UK supply contract

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

LEAVE A REPLY

Please enter your comment!
Please enter your name here